In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

Sofia Perea; Gloria Gonzalez; Annette W. Fothergill; William R. Kirkpatrick; Michael G. Rinaldi; Thomas F. Patterson

doi:10.1128/AAC.46.9.3039-3041.2002

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

Sofia Perea, Gloria Gonzalez, Annette W. Fothergill, William R. Kirkpatrick, Michael G. Rinaldi, Thomas F. Patterson

Research output: Contribution to journal › Article › peer-review

195 Scopus citations

Abstract

The interaction between caspofungin acetate and voriconazole was studied in vitro by using 48 clinical Aspergillus spp. isolates obtained from patients with invasive aspergillosis. MICs were determined by the NCCLS broth microdilution method. Synergy, defined as a fractional inhibitory concentration (FIC) index of <1, was detected in 87.5% of the interactions; an additive effect, defined as an FIC index of 1.0, was observed in 4.2% of the interactions; and a subadditive effect, defined as an FIC index of 1.0 to 2.0, was found in 8.3% of the interactions. No antagonism was observed. Animal models are required to validate the in vivo significance of these in vitro data presented for the combination of caspofungin and voriconazole.

Original language	English (US)
Pages (from-to)	3039-3041
Number of pages	3
Journal	Antimicrobial agents and chemotherapy
Volume	46
Issue number	9
DOIs	https://doi.org/10.1128/AAC.46.9.3039-3041.2002
State	Published - Sep 2002

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology

Access to Document

10.1128/AAC.46.9.3039-3041.2002

Cite this

@article{ad5360cfd8e04eeaa5a018a092d53b48,

title = "In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.",

abstract = "The interaction between caspofungin acetate and voriconazole was studied in vitro by using 48 clinical Aspergillus spp. isolates obtained from patients with invasive aspergillosis. MICs were determined by the NCCLS broth microdilution method. Synergy, defined as a fractional inhibitory concentration (FIC) index of <1, was detected in 87.5% of the interactions; an additive effect, defined as an FIC index of 1.0, was observed in 4.2% of the interactions; and a subadditive effect, defined as an FIC index of 1.0 to 2.0, was found in 8.3% of the interactions. No antagonism was observed. Animal models are required to validate the in vivo significance of these in vitro data presented for the combination of caspofungin and voriconazole.",

author = "Sofia Perea and Gloria Gonzalez and Fothergill, {Annette W.} and Kirkpatrick, {William R.} and Rinaldi, {Michael G.} and Patterson, {Thomas F.}",

year = "2002",

month = sep,

doi = "10.1128/AAC.46.9.3039-3041.2002",

language = "English (US)",

volume = "46",

pages = "3039--3041",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "9",

}

TY - JOUR

T1 - In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

AU - Perea, Sofia

AU - Gonzalez, Gloria

AU - Fothergill, Annette W.

AU - Kirkpatrick, William R.

AU - Rinaldi, Michael G.

AU - Patterson, Thomas F.

PY - 2002/9

Y1 - 2002/9

N2 - The interaction between caspofungin acetate and voriconazole was studied in vitro by using 48 clinical Aspergillus spp. isolates obtained from patients with invasive aspergillosis. MICs were determined by the NCCLS broth microdilution method. Synergy, defined as a fractional inhibitory concentration (FIC) index of <1, was detected in 87.5% of the interactions; an additive effect, defined as an FIC index of 1.0, was observed in 4.2% of the interactions; and a subadditive effect, defined as an FIC index of 1.0 to 2.0, was found in 8.3% of the interactions. No antagonism was observed. Animal models are required to validate the in vivo significance of these in vitro data presented for the combination of caspofungin and voriconazole.

AB - The interaction between caspofungin acetate and voriconazole was studied in vitro by using 48 clinical Aspergillus spp. isolates obtained from patients with invasive aspergillosis. MICs were determined by the NCCLS broth microdilution method. Synergy, defined as a fractional inhibitory concentration (FIC) index of <1, was detected in 87.5% of the interactions; an additive effect, defined as an FIC index of 1.0, was observed in 4.2% of the interactions; and a subadditive effect, defined as an FIC index of 1.0 to 2.0, was found in 8.3% of the interactions. No antagonism was observed. Animal models are required to validate the in vivo significance of these in vitro data presented for the combination of caspofungin and voriconazole.

UR - http://www.scopus.com/inward/record.url?scp=0036721037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036721037&partnerID=8YFLogxK

U2 - 10.1128/AAC.46.9.3039-3041.2002

DO - 10.1128/AAC.46.9.3039-3041.2002

M3 - Article

C2 - 12183266

AN - SCOPUS:0036721037

SN - 0066-4804

VL - 46

SP - 3039

EP - 3041

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 9

ER -

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this